New device aims to catch debris and prevent stroke during artery stenting
NCT ID NCT07277296
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called SwitchGuard NPS that is designed to catch loose debris and protect the brain during a procedure to open narrowed neck arteries. About 103 people with carotid artery stenosis who are at high risk for standard surgery will receive the device along with a stent. Researchers will track how many have a stroke, heart attack, or die within 30 days.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SwitchGuard™ NPS (a device that catches debris during stenting) used with the CGuard™ Prime 80 carotid stent
- What this could lead to
- If it works, this could offer a safer way to open blocked neck arteries and reduce the risk of stroke during the procedure.
- What could go wrong
- This is a small, early-stage study with no comparison group, so results may not apply to everyone. The device itself carries risks like stroke, heart attack, or death.
Why investors are watching
InspireMD is testing its SwitchGuard neuroprotection system, a device meant to catch debris during a carotid artery stenting procedure, in a 103-patient pivotal study. For a micro-cap company, this readout is a make-or-break event because a positive result could support regulatory approval and give the company its first commercial product. The trial uses a single-arm design, meaning all participants receive the device, which can speed up the study but also carries higher risk of unexpected safety issues.
If it works: If the study shows the device is safe and effective, InspireMD could seek approval to sell SwitchGuard, which would give the company a revenue-generating product. A successful readout might also attract partnership or acquisition interest from larger medical device firms.
If it fails: If the trial fails or shows safety problems, InspireMD may face significant delays or be unable to bring the product to market, which could be damaging for a company of its size. Clinical trials often fail, and a single-arm study without a comparison group can be harder to interpret, so the outcome is uncertain.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 103 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 82 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements. 2. Patient is diagnosed with carotid artery disease treatable with a Carotid Artery Stent via a Transcarotid Artery Revascularization approach and is either symptomatic or asymptomatic, defined as: Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack (TIA) or stroke within the last 6 months ipsilateral to the side of the stenosis OR asymptomatic carotid stenosis ≥ 80% 3. High Risk condition for CEA: at least one, as shown below: Comorbid conditions: Age ≥ 70 (maximum 82 years) CCS angina class 3-4 or unstable angina Congestive Heart Failure (CHF) NYHA class III-IV Left ventricular ejection fraction (LVEF) ≤ 35% MI ≥ 72 hours and \< 6 weeks pre-procedure Multi-vessel CAD (≥ 2 vessels \>70% stenosis) and history of angina Chronic Obstructive Pulmonary Disease (COPD) with FEV1\<50 Permanent contralateral cranial nerve injury/paralysis Restenosis from previous carotid endarterectomy (CEA) Planned coronary artery bypass grafting (CABG) or valve replacement surgery between 31-60 days after CAS Abdominal aortic aneurysm surgical repair or Endovascular repair is planned between 31 to 60 days after CAS Anatomic conditions: Occlusion of the contralateral CCA or ICA Prior radiation treatment to the neck or a radical neck dissection Severe bilateral ICA stenosis requiring treatment Target lesion at or above the level of the jaw (C2) or below the clavicle Severe tandem lesions Inability to extend the neck due to cervical disorders Laryngeal palsy or laryngectomy Prior head and neck surgery in the region of the carotid artery Tracheostomy or tracheostoma Spinal immobility of the neck Exclusion Criteria: 1. Patient had or will have an interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure 2. Patient had or will have open heart surgery or valvular intervention (percutaneous or surgical), or any major operation, within 30 days before or after the index carotid procedure 3. Vascular anatomy that would preclude safe sheath insertion or deliverability of stent 4. Previously placed stent in the ipsilateral ICA or CCA 5. Total occlusion or presence of a "string sign" of the ipsilateral ICA or CCA 6. Presence of a filling defect of the target lesion 7. Tandem lesions, which cannot be covered by a single CGuard Prime stent 8. Stenosis of the innominate artery or proximal CCA requiring revascularization 9. Open neck stoma 10. History of bleeding diatheses or coagulopathy 11. Hypercoagulable state 12. Alternative source of cerebral embolus, including but not limited to: Chronic atrial fibrillation Episode(s) of paroxysmal atrial fibrillation within the past 6 months or history of paroxysmal atrial fibrillation requiring chronic anticoagulation Knowledge of cardiac sources of embolus (e.g. left ventricular aneurysm, intracardiac filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm, or left atrial myxoma) Recently (\<60 days) implanted heart valve (either surgically or endovascularly) as a known source of emboli as confirmed on echocardiogram, Abnormal angiographic findings: ipsilateral intracranial or extracranial arterial stenosis (as determined by angiography or CTA/MRA 6 months prior to index procedure) greater in severity than the lesion to be treated; cerebral aneurysm \> 5mm; AVM (arteriovenous malformation) of the cerebral vasculature, or other abnormal angiographic findings Known sensitivity or allergy to nickel or titanium.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Carotid artery stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which patch keeps the carotid artery open longer?
- Can a new CT scanner see carotid plaques better?
- Could an arthritis drug shield heart and kidneys in metabolic syndrome?
- Could a double-barrel cholesterol drug shrink artery plaque better than statins alone?
- Balloon catheter may shield the brain from debris during artery stenting
- Blood test may flag heart danger before carotid surgery